The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | COMy 2020 highlights: smoldering myeloma, MRD and immunotherapy
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, gives an overview of the topics discussed during the COMy 2020 meeting. The main areas of discussion this year were smoldering myeloma, new drugs approved for multiple myeloma, CAR T-cell therapies and new monoclonal antibodies. The role of MRD in multiple myeloma was also discussed. The meeting this year was very successful with attendees from over 100 countries and thousands of people watching. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
